Clinical Trial Update: Mesenchymal Stromal/Stem Cells-Derived Exosomes (MSC-Exos) Therapy for Type 2 Diabetes Mellitus Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Mesenchymal Stromal/Stem Cells-Derived Exosomes (MSC-Exos) therapy for Type 2 Diabetes Mellitus is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Mesenchymal Stromal/Stem Cells-Derived Exosomes Therapy (MSC-Exos)

Snippet

Sponsor: Indonesia University | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: NOT_YET_RECRUITING